Fig. 4From: A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancerThe changes of SUVmax (a), tumor-to-liver ratio (b), and tumor-to-blood pool ratio (c) of HER2-positive and HER2-negative tumors over timeBack to article page